Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 23, Issue 11, Pages 552-559Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2012.06.009
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [5T32GM083831, CA157996]
- Cancer Prevention and Research Institute of Texas [HIRP100437, RP101243]
- Robert A. Welch Foundation [I-1733]
- Damon-Runyon Cancer Research Foundation
Ask authors/readers for more resources
Oncogenes and tumor suppressors regulate cell metabolism. Evidence demonstrates that tumorigenic mutations in these genes tend to orchestrate metabolic activity into a platform that promotes cell survival, growth, and proliferation. Recent work has shown that some metabolic enzymes are also mutated in cancer, and that these mutations may influence malignancy directly. Thus, these enzymes seem to function as oncogenes and tumor suppressors, and would appear to be compelling targets for therapeutic intervention. Here, we review several enzymes mutated in cancer - phosphoglycerate dehydrogenase, isocitrate dehydrogenases 1 and 2, succinate dehydrogenase, and fumarate hydratase - and discuss exciting new work that has begun to pull back the curtain on how mutations in these enzymes influence tumorigenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available